home / stock / ktta / ktta articles
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,34...
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene thera...
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.28% to 36,349...
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy o...
Shares of Salesforce, Inc. (NYSE: CRM) shares surged in pre-market trading after the company reported third-quarter financial results and issued ...
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with ...
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWS...
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the ...
2024-04-16 18:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...